Albany, New York, September 22, 2017: The global atopic dermatitis treatment market is projected to grow at over 12% during 2017-2027 and reach a value of around US$ 24 billion. Higher prevalence of atopic dermatitis is a key factor driving higher sales of atopic dermatitis products and services. These insights are according to a new research added to the database of Market Research Reports Search Engine (MRRSE). The report titled, “Atopic Dermatitis Treatment Market: Global Industry Analysis 2012-2016 and Opportunity Assessment 2017-2027” is a comprehensive source of information, providing key information on the future direction of this growing market.
In addition to growing incidences of atopic dermatitis, the market is impacted by growing R&D among pharmaceutical companies to launch safe and effective products to consolidate their position. Today, consumers are looking at safe and effective products to relieve signs & symptoms of atopic dermatitis quickly, and this has led to increased penetration of novel drugs and products in the market.
According to the report, North America remains the largest market for atopic dermatitis treatment products and services globally. The North America atopic dermatitis market is likely to grow at over 16% CAGR and surpass US$ 10 billion in revenues by 2027. In 2016, North America held nearly 30% revenue share of the global market.
In addition to North America, Western Europe remains another lucrative market for atopic dermatitis products and services globally. Ever-evolving end-user demand in Western Europe is influencing manufacturers to launch innovative products in the market. Owing to the growing trend of organic and chemical-free, there has been an increased preference towards creams and ointments that are safe to use.
Market Segmentation Highlights
According to the report, corticosteroids remain the highest-selling drugs in the global atopic dermatitis treatment market. However, owing to increasing preference for biological therapy, sales of corticosteroids are likely to witness a significant decline during the forecast period. The biological therapy segment is likely to grow at a robust CAGR of over 26%.
Topic procedure is currently the dominant route of administration, and the status quo is unlikely to change during the forecast period. By the end of forecast period, topical administration is likely to account for nearly 2/3 revenue share of the market.
Dermatology clinics are quickly gaining ground to become one of the leading distribution channels, but hospital pharmacies remain the largest in terms of revenue share. Currently, sales through hospital pharmacies account for nearly 33% revenue share of the market.
Leading companies profiled in the report include Fujisawa Healthcare, Regeneron Pharmaceuticals, Sanofi SA, Meda Pharmaceuticals, Allergan Plc., Novartis, Astellas Pharma Inc., Bristol-Myers Squibb, Aqua Pharmaceuticals (An Almirall Company), Bayer AG, Galderma SA, Anacor Pharmaceutical Inc., Pfizer, Dow Pharm, Connetics Corporation, Encore Dermatology, LEO Pharma, Velite Pharmaceutical, Biofrontera AG.
Browse Full Global Atopic Dermatitis Treatment Market Report with TOC : http://www.mrrse.com/atopic-dermatitis-treatment-industry
Market Research Reports Search Engine (MRRSE) is an industry-leading database of market intelligence reports. MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.
MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.
90, State Street
Albany, NY – 12207